2022
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004)
Bertz R, Donohue M, Madonia J, Bhardwaj R, Stringfellow J, Anderson M, Stock D, Morris B, Coric V, Croop R. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1003.Peer-Reviewed Original ResearchEffect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects (P2-2.001)
Bertz R, Anderson M, Collins J, Stringfellow J, Madonia J, Bharwaj R, Finley J, Stock D, Coric V, Croop R. Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects (P2-2.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.877.Peer-Reviewed Original ResearchP‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects
Bhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, Stock D, Coric V, Croop R, Bertz R. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Clinical Pharmacology In Drug Development 2022, 11: 889-897. PMID: 35304977, PMCID: PMC9311059, DOI: 10.1002/cpdd.1088.Peer-Reviewed Original ResearchConceptsBreast cancer resistance protein transporterPlasma concentration-time curveSingle oral doseGeometric mean ratiosConcentration-time curveP-glycoproteinOral doseHealthy subjectsSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistStrong P-glycoprotein inhibitorBreast cancer resistance protein (BCRP) inhibitionPeptide receptor antagonistTime 0Mean ratioP-glycoprotein inhibitorsP-glycoprotein transporterConcomitant administrationCrossover studyReceptor antagonistPreventive treatmentCyclosporineCoadministrationTransporter inhibitionPharmacokinetics
2020
Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)
Conway C, Dubowchik G, Croop R, Coric V. Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2145.Peer-Reviewed Original Research